Table 1 Demographic and clinical characteristics of DUX4 patients treated on AIEOP-BFM ALL protocols.
From: Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia
Characteristics | Total (N = 70) | AIEOP-BFM ALL 2000 (N = 33) | AIEOP-BFM ALL 2009 (N = 24) | AIEOP-BFM ALL 2017 (N = 13) |
|---|---|---|---|---|
Gender, No. (%) | ||||
Female | 33 (47.1) | 15 (45.5) | 10 (41.7) | 8 (61.5) |
Male | 37 (52.9) | 18 (54.5) | 14 (58.3) | 5 (38.5) |
Age at diagnosis, years, median, range | ||||
10.3 (2.3–18.4) | 9.5 (2.3–16.6) | 13.2 (3.3–18.4) | 9.5 (4.5–17.4) | |
Initial WBC (×109/L), No. (%) | ||||
<20 | 51 (72.9) | 26 (78.8) | 19 (79.2) | 6 (46.2) |
20 to <50 | 13 (18.6) | 4 (12.1) | 3 (12.5) | 6 (46.2) |
>50 | 6 (8.6) | 3 (9.1) | 2 (8.3) | 1 (7.7) |
Prednisone response, No. (%) | ||||
Good | 58 (82.9) | 29 (87.9) | 19 (79.2) | 10 (76.9) |
Poor | 9 (12.9) | 3 (9.1) | 4 (16.7) | 2 (15.4) |
Unknown | 3 (4.3) | 1 (3.0) | 1 (4.2) | 1 (7.7) |
PCR-MRD risk group, No. (%) | ||||
LR | 6 (8.6) | 5 (15.2) | 1 (4.2) | 0 |
IR | 47 (67.1) | 26 (78.8) | 12 (50.0) | 9 (69.2) |
HR | 15 (21.4) | 1 (3.0) | 10 (41.7) | 4 (30.8) |
Unknown | 2 (2.9) | 1 (3.0) | 1 (4.2) | 0 |
FCM-MRD risk group, No. (%) | ||||
FLR | 17 (24.3) | 9 (37.5)a | 5 (20.8) | 3 (23.1) |
FMR | 42 (60.0) | 21 (87.5)a | 13 (54.2) | 8 (61.5) |
FHR | 11 (15.7) | 3 (12.5)a | 6 (25.0) | 2 (15.4) |
Study risk group, No. (%) | ||||
SRG | 6 (8.6) | 5 (15.2) | 1 (4.2) | 0 |
MRG | 43 (61.4) | 24 (72.7) | 11 (45.8) | 8 (61.5) |
HRG | 21 (30.0) | 4 (12.1) | 12 (50.0) | 5 (38.5) |
